Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,520.00    -20.00 (-1.30%)
Bid:
1,522.00
Ask:
1,524.00
Spread: 2.00 (0.131%)
Market Cap: £3.20b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Stabilisation Notice

31 Mar 2015 15:27

RNS Number : 0377J
Citigroup Global Markets Limited
31 March 2015
 

31st March 2015

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Hikma Pharmaceuticals PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

The securities:

Issuer:

Hikma Pharmaceuticals PLC

Guarantor (if any):

Aggregate nominal amount:

$ TBC

Description:

Reg S registered

Offer price:

TBC

Other offer terms

TBC

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

1st April 2015

Stabilisation period expected to end no later than:

1st May 2015 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAJBMITMBTJBFA
Date   Source Headline
2nd Oct 20173:36 pmRNSTotal Voting Rights
28th Sep 20173:29 pmRNSHolding(s) in Company
25th Sep 201711:27 amRNSHolding(s) in Company
14th Sep 20173:52 pmRNSHolding(s) in Company
25th Aug 20178:41 amRNSHolding(s) in Company
17th Aug 20177:00 amRNSHikma announces licensing agreement with Takeda
17th Aug 20177:00 amRNSHalf-year Report
10th Aug 201710:05 amRNSDirector/PDMR Shareholding
10th Aug 201710:02 amRNSDirector/PDMR Shareholding
9th Aug 20179:54 amRNSDirector/PDMR Shareholding
4th Aug 20179:56 amRNSHolding(s) in Company
3rd Aug 20172:22 pmRNSNotice of Results
24th Jul 201710:53 amRNSHolding(s) in Company
4th Jul 201711:02 amRNSTotal Voting Rights
3rd Jul 20173:03 pmRNSHolding(s) in Company
30th Jun 20174:11 pmRNSHolding(s) in Company
26th Jun 20177:00 amRNSLeadership and Structural Changes to US Business
12th Jun 20174:31 pmRNSDirector/PDMR Shareholding
2nd Jun 20174:51 pmRNSTotal Voting Rights
31st May 20179:38 amRNSDirector/PDMR Shareholding
19th May 20172:44 pmRNSResult of AGM
19th May 20177:00 amRNSTrading Statement
15th May 20173:30 pmRNSDirector/PDMR Shareholding
11th May 20177:50 amRNSHikma update on ANDA for generic Advair Diskus
8th May 20179:23 amRNSChange of Registered Address
3rd May 20175:23 pmRNSTotal Voting Rights
3rd May 201710:37 amRNSChange of Registered Office
28th Apr 20172:30 pmRNSDirector/PDMR Shareholding
28th Apr 20171:57 pmRNSDirector/PDMR Shareholding
24th Apr 20173:35 pmRNSDirector/PDMR Shareholding
13th Apr 20178:58 amRNSDirector/PDMR Shareholding
13th Apr 20178:43 amRNSDirector/PDMR Shareholding
13th Apr 20178:42 amRNSDirector/PDMR Shareholding
13th Apr 20178:41 amRNSDirector/PDMR Shareholding
13th Apr 20178:36 amRNSDirector/PDMR Shareholding
11th Apr 20174:01 pmRNSDirector/PDMR Shareholding
7th Apr 201711:55 amRNSAnnual Financial Report
6th Apr 20177:00 amRNSHikma enters into settlement agreement with Jazz
3rd Apr 20173:59 pmRNSTotal Voting Rights
3rd Apr 20173:56 pmRNSBlock listing Interim Review
27th Mar 201711:13 amRNSHolding(s) in Company
23rd Mar 20179:30 amRNSDirector/PDMR Shareholding
15th Mar 20177:00 amRNSFinal Results
10th Mar 20177:30 amRNSHikma launches Desvenlafaxine Succinate Tablets
8th Mar 20174:01 pmRNSNotice of Results
8th Mar 20171:30 pmRNSDirector/PDMR Shareholding
1st Mar 20172:38 pmRNSTotal Voting Rights
13th Feb 20179:19 amRNSLicensing agreement with Orion for Easyhaler®
6th Feb 20172:27 pmRNSTotal Voting Rights
6th Feb 201712:47 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.